Ipsen reported strong Q2 results, exceeding the company-compiled estimates. Despite generics posing a threat to its lynchpin drug i.e. Somatuline, the promising trends for other offerings and less severe generics-driven headwinds prompted a guidance upgrade. Add to this the various other near-term readouts and balance flex being put to good use via the pursuit of newer growth bets and this French small pharma remains a very attractive sector bet.
28 Jul 2022
Strong Q2 + guidance upgrade; an atypical solid small pharma
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong Q2 + guidance upgrade; an atypical solid small pharma
Ipsen reported strong Q2 results, exceeding the company-compiled estimates. Despite generics posing a threat to its lynchpin drug i.e. Somatuline, the promising trends for other offerings and less severe generics-driven headwinds prompted a guidance upgrade. Add to this the various other near-term readouts and balance flex being put to good use via the pursuit of newer growth bets and this French small pharma remains a very attractive sector bet.